Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07111507 · ClinicalTrials.gov registry record · Phase 2

A Study of Tarlatamab for People With Prostate Cancer

A Phase 2 study of Metastatic Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
32
Enrollment target
10
Study locations

NCT07111507 is a Phase 2 study of Metastatic Prostate Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 32 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (83% lower). The trial reports 10 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07111507, a Phase 2 study of Metastatic Prostate Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
10
Study locations

Study Summary

The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).

Conditions Studied

Metastatic Prostate Cancer

Interventions

  • DRUG Tarlatamab

Study Locations (10)

New York

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

California

  • UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) - San Diego
  • University of California San Francisco - San Francisco

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-07-31
Est. Completion 2027-08-31
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07111507

The ClinicalTrials.gov registry entry for NCT07111507 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tarlatamab is the first listed.

NCT07111507 reports 10 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, California.

Frequently Asked Questions

What is clinical trial NCT07111507 about?

NCT07111507 is a clinical study titled "A Study of Tarlatamab for People With Prostate Cancer". The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refract...

What is the current status of trial NCT07111507?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-07-31. Estimated completion is 2027-08-31.

What conditions does trial NCT07111507 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer.

What interventions are being tested in trial NCT07111507?

The interventions under investigation include: Tarlatamab (DRUG).

Who is sponsoring clinical trial NCT07111507?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07111507 being conducted?

This trial has 10 study locations across California, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.